SecBot SecBot
6-K ·Filed Nov 10, 2026

MESO

MESOBLAST LTD
NEUTRAL
Impact 3/10
Horizonmonths Processed6d 8h ago SEC0001345099-26-000097
Notable filing: 6-K
Actionable Insight • Neutral

Monitor the CLBP Phase 3 readout in H2 CY2027 and the adult SR-aGvHD interim analysis in Q4 CY2027 as key catalysts. The LVAD BLA filing timeline and potential cardiopulmonary partnership are also important milestones. Ryoncil revenue trajectory in FY2027 will signal commercial execution.

DirectionNeutral
Confidencehigh
Horizonmonths

Drugs in focus

MESO drug pipeline →

rexlemestrocel-L

▲ Bullish Named in this 6-K
Impact
Phase
Phase 3 / Filed BLA
Time to market
LVAD/heart failure BLA now under FDA review with modular review requested — no PDUFA date set yet (potentially 2027 if accepted). CLBP indication likely 2028 at earliest (topline mid-2027, BLA Q3 2027, FDA action 2028).
Next catalyst
None dated

What to watchMesoblast just filed a BLA for rexlemestrocel-L in LVAD/heart failure, the next catalyst is FDA acceptance and a PDUFA date. Meanwhile, the much larger CLBP opportunity (7M+ US patients, non-opioid approach) is advancing with Phase 3 enrollment complete and topline due mid-2027. The company already generates real revenue from Ryoncil (~$110-120M FY2026 guidance), de-risking the story vs. pre-revenue biotechs. Monitor (1) FDA's action on the LVAD BLA modular review, (2) CLBP Phase 3 topline in mid-2027, and (3) Ryoncil revenue growth trajectory.

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+1
Entry
$13.65
T+0 close · Nov 10, 2026 · via day close
Latest settled
−4.03%
T+1 · $13.10 · next T+5 tomorrow
Vs SPY
−3.68%
α at T+1
Latest observation
−0.86%
T+2 · FF3 residual α
  1. T+0 · Nov 11 $13.65entry
  2. T+1 · 5d ago −4.03%α −3.68% · $13.10
  3. T+3 · todayOpen
  4. T+5 · tomorrow Pending
  5. T+20 · in 23d Pending
  6. T+60 · in 3mo Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Mesoblast held its 2026 Annual General Meeting, reporting FY2026 Ryoncil net revenue of $115M, completing enrollment in the pivotal Phase 3 CLBP trial, and announcing FDA alignment for a BLA filing for rexlemestrocel-L in LVAD patients. The company appointed an interim COO to prepare for commercial scale-up, while two directors retired and one new director was elected. The filing is a routine AGM update with no new financial data beyond previously reported figures.

Key Facts

  • FY2026 Ryoncil net revenue of $115M, gross profit of $110M excluding amortization
  • Phase 3 CLBP trial fully enrolled with 350 patients; readout expected H2 CY2027
  • FDA alignment obtained for BLA filing of rexlemestrocel-L in LVAD patients with GI bleeding
  • Adult SR-aGvHD registrational trial commenced, targeting 40 US sites; interim analysis expected Q4 CY2027
  • Dr. Gregory George appointed interim COO; Dr. Eric Rose steps away from Board to focus as CMO
  • William Burns and Philip Krause retired from the Board; Jon Voigtman elected as director
  • All AGM resolutions carried, including adoption of remuneration report and equity incentive plans

Financial Impact

FY2026 Ryoncil net revenue $115M, gross profit $110M; company remains unprofitable with accumulated losses of $1.07B per prior 20-F

revenuegross profit

Risk Factors

  • CLBP Phase 3 trial may fail to meet primary endpoint
  • Adult SR-aGvHD trial enrollment or results may disappoint
  • Company remains unprofitable with significant accumulated losses
  • Pipeline candidates face clinical and regulatory risks

Investment Themes

Documents Analyzed

This report is based on 11 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001345099-26-000097
Exhibit: exhibit9932026agmappendi.htm0001345099-26-000097
Exhibit: exhibit9942026agmappendi.htm0001345099-26-000097
Exhibit: exhibit9912026agmappendi.htm0001345099-26-000097
Exhibit: exhibit9962026agmappendi.htm0001345099-26-000097
Exhibit: exhibit9952026agmappendi.htm0001345099-26-000097
Document: form6-kxpressreleasecoverf.htm0001345099-26-000097
Document: 0001345099-26-000097-index-headers.html0001345099-26-000097
Document: 0001345099-26-000097-index.html0001345099-26-000097
Document: 0001345099-26-000097.txt0001345099-26-000097
Earnings Context (Synthetic; results releases only)0001345099-26-000097

Track record

25 reports on MESO

Performance horizon

7 of 15 bullish or bearish reports moved the stock their way by T+1. Best: +24.95% at T+20 after the Jul 30, 2026 report. 10 of 15 went positive at some point.

Filters
  1. Nov 16, 2026today 6-K Neutral 2/10 Entry $13.25 Now $12.45 −6.04% settles Nov 17
  2. Nov 10, 20266d ago 6-K Neutral 3/10 Viewing Entry $13.65 to $13.10 Now $12.45 −8.79% ▼ −4.03% −3.68% vs SPY
  3. Nov 2, 202614d ago 6-K Neutral 2/10 Entry $14.77 to $14.29 Now $12.45 −15.71% ▼ −3.25% −4.90% vs SPY
  4. Oct 29, 202618d ago 6-K Bullish 6/10 No price data
  5. Oct 28, 202619d ago Press Release Bullish 6/10 Entry $15.67 to $15.16 Now $12.45 −20.55% ▼ −3.25% −1.48% vs SPY
  6. Oct 15, 20264w ago 6-K Bullish 6/10 Entry $13.28 to $11.95 Now $12.45 −6.25% ▼ −10.02% −10.44% vs SPY
  7. Oct 15, 20264w ago 6-K Neutral 2/10 Entry $13.95 to $13.28 Now $12.45 −10.75% ▼ −4.80% −3.70% vs SPY
  8. Oct 13, 20264w ago 6-K Mixed 6/10 Entry $13.90 to $13.79 Now $12.45 −10.40% ▼ −0.76% +0.33% vs SPY
  9. Sep 23, 20267w ago 6-K Neutral 3/10 Entry $15.48 to $15.12 Now $12.45 −19.57% ▼ −2.33% −2.87% vs SPY
  10. Aug 27, 202611w ago 20-F Bullish 6/10 Entry $18.18 to $17.44 Now $12.45 −31.52% ▼ −4.07% −3.84% vs SPY
Showing 10 of 25

US Market Status

Market Closed · Opens in 6h 37m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 10, 2026